gebasaxturev
AXP000123.1 · Oncolytic virus
- Platform
- coxsackievirus A21 (Kuykendall strain, wild-type)
- Originator
- Viralytics
- Sponsor
- Merck Sharp & Dohme
Names
| Name | Type | Source |
|---|---|---|
| gebasaxturev | preferred name, INN | curator, ncit |
| CAVATAK | brand | ncit |
| V937 | code | ncit |
| CVA21 ambiguous | synonym | ncit |
Virus
- Role
- Oncolytic
- Family
- Picornaviridae
- Virus
- coxsackievirus A21 (NCBI Taxonomy 12069)
- Strain
- Kuykendall
- Replication
- replicating
- Modifications
- none (wild-type isolate)
- Route
- intratumoral, intravenous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C61493
Approvals
No regulatory approval recorded.
Clinical trials (14)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04521621 | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | Terminated | Phase 1/2 | 2020-10-28 | 2023-07-25 | 76 | Neoplasm Metastasis |
| NCT04303169 | Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) | Completed | Phase 1/2 | 2020-06-26 | 2025-09-24 | 146 | Melanoma |
| NCT04152863 | Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011) | Terminated | Phase 2 | 2020-06-05 | 2023-07-12 | 85 | Advanced/Metastatic Melanoma |
| NCT03408587 | CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) | Completed | Phase 1 | 2018-01-29 | 2019-05-22 | 11 | Liver Metastases; Uveal Melanoma |
| NCT02824965 | Pembrolizumab + CVA21 in Advanced NSCLC | Unknown | Phase 1 | 2017-08-09 | 2021-07-01 | 11 | Non-Small Cell Lung Cancer |
| NCT02565992 | Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA) | Completed | Phase 1 | 2015-12-17 | 2019-11-04 | 36 | Melanoma |
| NCT02307149 | Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI) | Completed | Phase 1 | 2015-05-05 | 2019-11-05 | 50 | Melanoma |
| NCT02316171 | CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON) | Completed | Phase 1 | 2015-01-16 | 2016-03-14 | 16 | Non-muscle Invasive Bladder Cancer |
| NCT02043665 | CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200) | Completed | Phase 1 | 2013-12-18 | 2020-01-10 | 85 | Bladder Cancer; Non-small Cell Lung Cancer |
| NCT01636882 | CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext) | Completed | Phase 2 | 2012-07-03 | 2016-04-06 | 16 | Melanoma |
| NCT01227551 | A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM ) | Completed | Phase 2 | 2011-12-29 | 2016-04-06 | 57 | Malignant Melanoma |
| NCT00832559 | A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients (VLA-X06) | Terminated | Phase 1 | 2009-01-27 | 2011-07-28 | 4 | Head and Neck Cancer |
| NCT00636558 | Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04) | Completed | Phase 1 | 2008-02-29 | 2012-01-12 | 8 | Breast Cancer; Melanoma; Prostate Cancer |
| NCT00438009 | A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03) | Completed | Phase 1 | 2007-05-16 | 2009-08-28 | 9 | Stage IV Melanoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42190314 | Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02C. | ESMO open | 2026 | name in abstract: gebasaxturev |
| PMID 39775043 | Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial. | Nature medicine | 2025 | cited by trial NCT04303169 |
| PMID 36445410 | A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study. | Cancer immunology, immunotherapy : CII | 2023 | cited by trial NCT02565992 |
| PMID 36651961 | Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma. | Journal of cancer research and clinical oncology | 2023 | cited by trial NCT03408587 |
| PMID 36669791 | Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. | Journal for immunotherapy of cancer | 2023 | cited by trial NCT02043665 |
| PMID 35387488 | Reverse-Phase Ultra-Performance Chromatography Method for Oncolytic Coxsackievirus Viral Protein Separation and Empty to Full Capsid Quantification. | Human gene therapy | 2022 | cited by trial NCT04152863 |
| PMID 36564126 | Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study. | Journal for immunotherapy of cancer | 2022 | cited by trial NCT02307149 |
| PMID 34464163 | Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021 | cited by trial NCT01227551 |
| PMID 31273010 | Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2019 | cited by trial NCT02316171 |
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40932352 | Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2025 | name in title: CVA21 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40750724 | Role of Antidrug Antibodies in Oncolytic Viral Therapy: A Dynamic Modelling Approach in Cancer Patients Treated with V937 Alone or in Combination. | Clinical pharmacokinetics | 2025 | name in title: V937 |
| PMID 38745749 | Oncolytic virus V937 in combination with PD-1 blockade therapy to target immunologically quiescent liver and colorectal cancer. | Molecular therapy. Oncology | 2024 | name in title: V937 |
| PMID 39037559 | Disentangling Anti-Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab. | Clinical pharmacology and therapeutics | 2024 | name in title: V937 |
| PMID 39207089 | Treatment of malignant melanoma with coxsackievirus A21 (V937): An emerging oncolytic virotherapy. | Experimental dermatology | 2024 | name in title: V937 |
| PMID 36299168 | Oncolytic virus preclinical toxicology studies. | Journal of applied toxicology : JAT | 2023 | name in abstract: CAVATAK |
| PMID 37170933 | Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling. | Clinical pharmacology and therapeutics | 2023 | name in title: V937 |
| PMID 37771727 | A physiologically based pharmacokinetic model for V937 oncolytic virus in mice. | Frontiers in pharmacology | 2023 | name in title: V937 |
| PMID 34277838 | Current status of intralesional agents in treatment of malignant melanoma. | Annals of translational medicine | 2021 | name in abstract: CAVATAK |
| PMID 34366859 | Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration. | Frontiers in pharmacology | 2021 | name in title: V937 |
| PMID 32162802 | Intratumoral Immunotherapy-Update 2019. | The oncologist | 2020 | name in abstract: CAVATAK |
| PMID 30261620 | The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers. | Cancers | 2018 | name in abstract: CAVATAK |
| PMID 30190880 | Intralesional treatment for advanced melanoma: what's on the horizon? | Melanoma management | 2016 | name in abstract: CAVATAK |
| PMID 24301265 | Intralesional immunotherapy for melanoma. | Journal of surgical oncology | 2014 | name in abstract: CAVATAK |
Unconfirmed matches (7)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42625927 | Updated oncolytic viruses for the treatment of bladder cancer: a systematic review. | Iranian journal of microbiology | 2026 | name in abstract: V937 |
| PMID 40328704 | [Preparation and antitumor activity characterization of oncolytic nanoparticles encapsulating CVA21]. | Sheng wu gong cheng xue bao = Chinese journal of biotechnology | 2025 | name in title: CVA21 |
| PMID 35024440 | SEC coupled with in-line multiple detectors for the characterization of an oncolytic Coxsackievirus. | Molecular therapy oncolytics | 2022 | name in abstract: V937 |
| PMID 28025712 | A cluster of coxsackievirus A21 associated acute respiratory illness: the evidence of efficient transmission of CVA21. | Archives of virology | 2017 | name in title: CVA21 |
| PMID 24695547 | The evolution of Vp1 gene in enterovirus C species sub-group that contains types CVA-21, CVA-24, EV-C95, EV-C96 and EV-C99. | PloS one | 2014 | name in title: CVA21 |
| PMID 24722726 | Recombination in the evolution of enterovirus C species sub-group that contains types CVA-21, CVA-24, EV-C95, EV-C96 and EV-C99. | PloS one | 2014 | name in title: CVA21 |
| PMID 12572466 | [Inhibition of 5 compounds from Bidens bipinnata on leukemia cells in vitro]. | Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials | 1997 | name in abstract: V937 |
Notes
Unmodified coxsackievirus A21, brand CAVATAK; renamed V937 after Merck acquired Viralytics in 2018. Merck has since stopped the programme. INN gebasaxturev.
How to cite
gebasaxturev (AXP000123.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000123.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.